Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 10/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.73 |
| ▸ | BRAF | P15056 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 4/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14040826 | 0.88 | PDGFRB (0.57) | PDGFRBPDGFRABRAFEGFRERBB2 | |
| SCHEMBL3917671 | 0.87 | FBP1 (0.59) | PDGFRBPDGFRABRAFEGFRERBB2 | |
| SCHEMBL3909786 | 0.85 | PDGFRB (1.00) | PDGFRBPDGFRABRAFEGFRLCK | |
| SCHEMBL3908116 | 0.84 | PDGFRB (0.73) | PDGFRBPDGFRAEGFRERBB2MAPT | |
| SCHEMBL3911063 | 0.84 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRERBB2LCK | |
| SCHEMBL7697848 | 0.83 | PDGFRB (0.56) | PDGFRBPDGFRABRAFEGFRTP53 | |
| SCHEMBL7692274 | 0.77 | PDGFRB (0.71) | PDGFRBPDGFRAEGFRPOLBMAPT | |
| SCHEMBL3906854 | 0.76 | PDGFRB (0.61) | PDGFRBPDGFRAEGFRTP53POLB | |
| SCHEMBL12857969 | 0.75 | BRAF (1.00) | BRAF | |
| SCHEMBL22407306 | 0.75 | PDGFRB (0.71) | PDGFRBPDGFRAEGFRLCKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100390155-C | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | claimed |
| EP-0991628-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2005-01-12 | — | — | EP | claimed |
| CN-1140516-C | Can inhibit platelet-derived growth factor and/or p56lckQuinoline and quinoxaline compounds of tyrosine kinases | ���µ�˹ҩ�﹫˾ | 2004-03-03 | — | — | CN | claimed |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | AVENTIS PHARMACEUTICALS INC. | 2003-07-31 | — | — | US | claimed |
| CN-1342151-A | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (US) | 2002-03-27 | — | — | CN | claimed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | claimed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | claimed |
| CN-1261354-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | CN | claimed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| CN-100390155-C | Quinoline and quinoxaline compounds | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | disclosed |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6846815-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-25 | — | — | US | disclosed |
| EP-0991628-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| CN-1261354-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561ck tyrosine kinases | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | CN | disclosed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, ABL1 | PDGFRB 39/4885PDGFRA 45/4885BRAF 722/4885 |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | LCK, NFATC1, MAP2K2 | PDGFRB 106/4885PDGFRA 299/4885BRAF 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.